# OnCo record stk11-keap1-loss (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/stk11-keap1-loss/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "stk11-keap1-loss" ;
  schema:name "STK11 or KEAP1 loss in KRAS-mutant lung adenocarcinoma"@en ;
  schema:alternateName "STK11 mutation"@en, "LKB1 loss"@en, "KEAP1 mutation"@en, "STK11/KEAP1 co-mutation"@en, "KL subtype"@en ;
  schema:description "Two genes that, when broken in a lung cancer that also has a faulty KRAS gene, predict that immunotherapy will work much less well. In a lung cancer with a normal KRAS gene the same faults appear to make no difference."@en ;
  schema:url <https://onco.cc/biomarkers/stk11-keap1-loss/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1158/2159-8290.CD-18-0099>, <https://doi.org/10.1158/1078-0432.CCR-17-1841>, <https://doi.org/10.1016/j.jtho.2021.10.013>, <https://www.cbioportal.org/study/summary?id=nsclc_pd1_msk_2018> ;
  onco:tag "biomarker", "immunotherapy" ;
  onco:related <https://onco.cc/biomarkers/kras-g12c/>, <https://onco.cc/biomarkers/kras-g12d/>, <https://onco.cc/biomarkers/pd-l1-tps/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/stk11/>, <https://onco.cc/targets/keap1/>, <https://onco.cc/targets/kras/> ;
  onco:pathways <https://onco.cc/pathways/t-cell-exhaustion/>, <https://onco.cc/pathways/keap1-nrf2/>, <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/stk11-keap1/>, <https://onco.cc/terms/kras-mutation-subtypes/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/resistance/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kras-nsclc-cancer-discov-2018/>, <https://onco.cc/key-papers/paper-arbour-kras-co-mutation-outcomes-ccr-2018/>, <https://onco.cc/key-papers/paper-ricciuti-stk11-keap1-kras-immunotherapy-jto-2022/>, <https://onco.cc/key-papers/paper-keynote-042-tmb-mutations-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/> .